+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of regimens containing quabodepistat for treating rifampicin-resistant or multidrug-resistant pulmonary tuberculosis in this Phase 3, randomized, open-label, multicenter trial. Participants are divided into two groups based on fluoroquinolone susceptibility and randomized to receive either experimental or control treatment regimens. The study aims to provide shorter, well-tolerated treatment options for drug-resistant tuberculosis. Participants with fluoroquinolone-susceptible tuberculosis are randomized to a 4-month experimental regimen including bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen with bedaquiline, pretomanid, linezolid, and moxifloxacin. Those with fluoroquinolone-resistant tuberculosis receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. Doses vary by drug and regimen, with some adjustments permitted for toxicity. Participants are followed for approximately 16 months after randomization, with evaluations including sputum samples, chest X-rays, and monitoring of adverse events. The main outcome measured is the proportion of participants with unfavorable outcomes at 12 months post-randomization. Other assessments include treatment-emergent adverse events, sputum culture conversion, relapse, and reinfection. Follow-up visits may extend to week 72 for ongoing safety or relapse monitoring.

Age: 14Years +All GendersPhase 3
42 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of a dietary supplement on the gut microbiome of healthy term infants aged around 5 months. The study is a double-blind, randomized, placebo-controlled nutritional trial designed to compare changes in the fecal microbiome composition between infants receiving the supplement and those receiving a placebo over a 5-month period. The goal is to understand how the supplement influences gut health and related biological markers. Participants are randomly assigned to one of two groups an experimental group receiving the dietary supplement and a control group receiving a placebo, both provided in powder form. Parents dissolve the powder in lukewarm formula or breastmilk and feed it to their infants using a supplied feeding beaker. The intervention lasts for 5 months, with the supplement or placebo given daily during this time. Throughout the study, infants undergo regular assessments including stool sample collection for microbiome and metabolic analysis, blood tests for immune health, measurements of growth such as weight and length, bone quality evaluation, and monitoring of gastrointestinal symptoms and infant illness. Dietary intake and neurodevelopment are also tracked using questionnaires and standardized tools. The trial lasts for 5 months of intervention with multiple clinic visits for data collection and monitoring.

Age: 19Weeks - 21WeeksAll GendersPhase Not Applicable
2 locations